Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

501.42 -2.08 (-0.41%)
Delayed Quote Updated: 1:42 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
News headline image
2 Safe-and-Steady Stocks with Promising Prospects and 1 We Turn Down
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi... 
Via StockStory
Topics Energy
News headline image
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ↗
One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential. 
Via The Motley Fool
News headline image
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ↗
Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward... 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. ↗
This biotech player is firing on all cylinders. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Healthcare Stocks to Target This Week and 1 We Avoid
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry... 
Via StockStory
News headline image
2 Healthcare Stocks That Just Delivered Great News for Investors ↗
And there could be more positive developments ahead. 
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles. 
Via The Motley Fool
News headline image
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 ↗
Don't read too much into this year's lackluster performance. Near-term catalysts are firming up. 
Via The Motley Fool
News headline image
Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback? ↗
This company has had plenty of setbacks in recent years, but it generally bounces back. 
Via The Motley Fool
News headline image
2 Reasons to Like VRTX (and 1 Not So Much)
Vertex Pharmaceuticals has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.... 
Via StockStory
Topics Stocks
News headline image
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? ↗
With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride. 
Via The Motley Fool
News headline image
My Top 5 Favorite Stocks for an Uncertain Market ↗
These players offer a certain level of stability in any market environment. 
Via The Motley Fool
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company’s... 
Via MarketBeat
News headline image
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality. 
Via The Motley Fool
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Brush Off
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a... 
Via MarketBeat
News headline image
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal... 
Via MarketBeat
News headline image
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD... 
Via StockStory
Topics Artificial Intelligence
News headline image
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock ↗
The company has tremendous prospects. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Why CRISPR Therapeutics Stock Rocked the Market Last Month ↗
The company had fallen out of investor favor; its recovery was impressive. 
Via The Motley Fool
News headline image
Where Will CRISPR Therapeutics Stock Be in 5 Years? ↗
CRISPR's expanding pipeline could unlock significantly more value by 2031. 
Via The Motley Fool
News headline image
3 Market-Beating Stocks for Long-Term Investors
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y... 
Via StockStory
News headline image
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗
They could both outperform the market over the medium term, but one appears to have a clear edge. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.61% on an annualized basis producing an average annual return of 14.84%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
News headline image
3 Stocks Whose Competitive Walls Tower Over Nvidia's ↗
A solid moat favors revenue growth, and that's good news for investors. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 ↗
We'll know a little more about the company's prospects by the end of the year. 
Via The Motley Fool
News headline image
1 S&P 500 Stock with Exciting Potential and 2 We Ignore
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Stocks
News headline image
If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on an annualized basis producing an average annual return of 14.56%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
News headline image
2 Large-Cap Stocks to Research Further and 1 We Question
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m... 
Via StockStory
News headline image
Inflation Is Rising Again. History Says These 2 Stocks Are Among the Smartest Places to Hide ↗
Inflation affects corporations differently. These two have the tools to navigate the challenge better than most. 
Via The Motley Fool
Topics Economy Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.